Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00978822 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

A Phase 2 study, sponsored by Henry Ford Health System.

Terminated
Registry status
Phase 2
Development phase
5
Enrollment target

NCT00978822: Clinical Trial Phase 2 study, sponsored by Henry Ford Health System.

NCT00978822 is a Phase 2 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00978822, a Phase 2 study, was terminated before completion, sponsored by Henry Ford Health System.

TERMINATED
Registry status
Phase 2
Development phase
5 participants
Enrollment target

Study Summary

This study is designed to assess how rapidly and how safely Clevidipine can be used to control high Blood Pressure in patients with subarachnoid hemorrhage which is a type of brain bleed that happens because of a weak balloon like structure in one of the brain vessels. Control of blood pressure is of high value in preventing this balloon that ruptured and bled from rebleeding. The ultimate cure would be to shut down the aneurysm by a surgical procedure. Clevidipine is a drug that can lower blood pressure and it is given through the vein as a continuous infusion. It is a very short acting drug which is important in controlling labile blood pressure condition with rapid changes between up and down. This trial will test for its rapid actions and check for any side effects and possibly any other potential benefit.

Primary Outcome

All patients reached the SBP target after initiation of the first infusion within 14.2 ± 6.4 min (n = 5, range 7-22 min) Study closed October 2012

Interventions

  • DRUG Clevidipine butyrate injectable emulsion

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2009-06
Est. Completion 2012-12
Phase Phase 2
Henry Ford Health System

234 total trials

Why NCT00978822 stopped before completion

NCT00978822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Clevidipine butyrate injectable emulsion is the first listed.

NCT00978822 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00978822 about?

NCT00978822 is a clinical study titled "Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage". This study is designed to assess how rapidly and how safely Clevidipine can be used to control high Blood Pressure in patients with subarachnoid hemorrhage which is a type of brain bleed that happens because of a weak balloon like structure in one of the brain vessels. Control of blood pressure is o...

What is the current status of trial NCT00978822?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2009-06. Estimated completion is 2012-12.

What interventions are being tested in trial NCT00978822?

The interventions under investigation include: Clevidipine butyrate injectable emulsion (DRUG).

Who is sponsoring clinical trial NCT00978822?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00978822's enrollment target sits among peer trials

5 2000th of 2000 the lowest of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00978822, the US trial registry maintained by the National Library of Medicine. NCT00978822 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.